PFN62958

PFN62958 is a useful peptide linker for synthesis of PSMA-617 (vipivotide tetraxetan), which is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA-617 originally was developed at the German Cancer Research Center and the Heidelberg University Hospital. ABX held the exclusive license to bring the treatment, which targets prostate-specific membrane antigen (PSMA), through early clinical development. is a tris(tert-butyl)-protected JUN68744 derivative. 

PFN62958

Furin Substrate

Polymyxin B nonapeptide TFA

MC-Gly-Gly-Gly-PAB

MC-GGFG-PAB

MC-Gly-Gly-Phe-Gly-PAB-PNP

otbu-Glu(otbu)-urea-Lys(Ahx)